UBS analyst AJ Rice lowered the firm’s price target on Cross Country Healthcare (CCRN) to $9 from $16.50 and keeps a Neutral rating on the shares. The company announced the termination of its merger agreement with Aya Healthcare, which triggers a $20M termination fee payable to Cross Country, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCRN:
- Citizens JMP upgrades Cross Country Healthcare after end of merger
- Cross Country Healthcare: Hold Rating Amid Acquisition Termination and Uncertain Financial Trajectory
- Cross Country Healthcare price target lowered to $8.65 from $12.29 at Jefferies
- Cross Country upgraded to Outperform from Market Perform at Citizens JMP
- Cross Country Healthcare: Navigating Post-Acquisition Challenges with Financial Stability and Growth Potential